http://www.acc.org/Feed?clinicalTopicID=a6997643-d7bf-4b8d-b578-d65877161636 Clinical Topic Feed: Novel Agents en /Latest-in-Cardiology/Journal-Scans/2026/05/18/18/10/New-Studies-Add-to-Evidence Treatment of patients following ischemic stroke was the focus of three separate studies published in JAMA, two of which involved use of intravenous tenecteplase and the other involving thrombectomy plus intra-arterial alteplase. 1779219300000 Articles and Stories /Latest-in-Cardiology/Articles/2026/05/19/15/49/JACC-Spotlight-Issue-2026-Dyslipidemia-Guideline A special JACC Spotlight Issue supporting the recently published 2026 ACC/AHA Guideline on the Management of Dyslipidemia, offers commentaries that provide a comprehensive overview of the new guideline recommendations and expert insights into understanding the science behind the recommendations... 1779206040000 Articles and Stories /Latest-in-Cardiology/Articles/2026/05/01/01/JACC-in-a-Flash Featured topics and Editors' Picks from all of ACC's JACC Journals. 1777637400000 Articles and Stories /Latest-in-Cardiology/Articles/2026/05/01/01/Journal-Wrap The hottest research from various peer-reviewed journals – handpicked weekly by the ACC. 1777637340000 Articles and Stories /Latest-in-Cardiology/Articles/2026/04/01/01/Journal-Wrap The hottest research from various peer-reviewed journals – handpicked weekly by the ACC. 1775045400000 Articles and Stories /Latest-in-Cardiology/Articles/2026/03/25/21/27/sat-345pm-vesaliuscv-acc-2026 The PCSK9 inhibitor evolocumab reduced the risk of a first major cardiovascular event in patients with diabetes without known significant atherosclerosis, according to a prespecified subgroup analysis of the VESALIUS-CV trial, presented during a Late-Breaking Clinical Trial session at ACC.26 in New Orleans and simultaneously published in JAMA. 1774730760000 Articles and Stories /Latest-in-Cardiology/Articles/2026/03/25/21/27/sat-345pm-kardinal-acc-2026 A monthly dose of the novel drug tonlamarsen significantly reduced plasma angiotensinogen (AGT) levels in patients with uncontrolled hypertension compared with a single dose of the drug followed by a placebo, but its impact on blood pressure was less clear, according to results from the KARDINAL trial presented at ACC.26 in New Orleans and simultaneously published in JACC. 1774730700000 Articles and Stories /Latest-in-Cardiology/Articles/2026/03/18/00/50/eagles-eye-view-18mar2025 In this week’s View, Dr. Eagle looks at data from the STS/ACC TVT Registry on off label transcatheter valve interventions that demonstrate reduced residual tricuspid regurgitation (TR) and improved quality of life. 1773842400000 Articles and Stories /Latest-in-Cardiology/Journal-Scans/2026/03/13/15/20/ACC-AHA-Release-New-Clinical-Guideline-For-Managing-Dyslipidemia The new ACC/AHA Guideline on the Management of Dyslipidemia offers a comprehensive “one-stop shop” for addressing the evaluation, management and monitoring of individuals with dyslipidemias, including high blood cholesterol, hypertriglyceridemia, and elevated lipoprotein(a) (Lp[a]). 1773415860000 Articles and Stories /Latest-in-Cardiology/Journal-Scans/2026/02/26/19/59/REVELUTION-More-Coronary-Plaque-Progression-With-Leuprolide-Than-Relugolix-in-Prostate-Cancer In men with localized prostate cancer (PCa) treated with radiation and androgen-deprivation therapy (ADT), treatment with the gonadotropin-releasing hormone (GnRH) leuprolide was associated with a significant 12-month increase in coronary artery plaque volume when compared with treatment with relugolix, according to a brief report of the REVELUTION trial published Feb. 18 in JAMA. 1772199900000 Articles and Stories